Medicare will only cover a new Alzheimer’s drug that costs $28,000 a year for patients who are enrolled in clinical trials, President Joe Biden’s administration announced preliminarily Tuesday.
Aduhelm, made by Biogen, was approved by drug regulators last year. Since then, the Centers for Medicare & Medicaid Services (CMS) has been assessing whether to cover the drug.
